The FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) on July 23, 2026, to recommend BPC-157 for the Section 503A bulks list, following its earlier removal from Category 2 restrictions in April 2026. This advisory step addresses prior safety concerns over immunogenicity and limited human data but does not itself place the peptide on Category 1, which requires formal notice-and-comment rulemaking that typically spans several additional months. Traders monitor subsequent FDA actions on the recommendation, any parallel Category 1 nominations such as for pentadecapeptide, and broader agency priorities on compounding access versus risk evaluation. No final resolution has occurred as of mid-August 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedNEW
Aug 31, 2026
August 31, 2026
8%
December 31, 2026
42%
$2,789 Vol.
August 31, 2026
$1,083 Vol.
8%
December 31, 2026
$1,706 Vol.
42%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) on July 23, 2026, to recommend BPC-157 for the Section 503A bulks list, following its earlier removal from Category 2 restrictions in April 2026. This advisory step addresses prior safety concerns over immunogenicity and limited human data but does not itself place the peptide on Category 1, which requires formal notice-and-comment rulemaking that typically spans several additional months. Traders monitor subsequent FDA actions on the recommendation, any parallel Category 1 nominations such as for pentadecapeptide, and broader agency priorities on compounding access versus risk evaluation. No final resolution has occurred as of mid-August 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Market Opened: Jun 22, 2026, 10:10 PM ET
Volume
$2,789End Date
Dec 31, 2026Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) on July 23, 2026, to recommend BPC-157 for the Section 503A bulks list, following its earlier removal from Category 2 restrictions in April 2026. This advisory step addresses prior safety concerns over immunogenicity and limited human data but does not itself place the peptide on Category 1, which requires formal notice-and-comment rulemaking that typically spans several additional months. Traders monitor subsequent FDA actions on the recommendation, any parallel Category 1 nominations such as for pentadecapeptide, and broader agency priorities on compounding access versus risk evaluation. No final resolution has occurred as of mid-August 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,789End Date
Dec 31, 2026Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) on July 23, 2026, to recommend BPC-157 for the Section 503A bulks list, following its earlier removal from Category 2 restrictions in April 2026. This advisory step addresses prior safety concerns over immunogenicity and limited human data but does not itself place the peptide on Category 1, which requires formal notice-and-comment rulemaking that typically spans several additional months. Traders monitor subsequent FDA actions on the recommendation, any parallel Category 1 nominations such as for pentadecapeptide, and broader agency priorities on compounding access versus risk evaluation. No final resolution has occurred as of mid-August 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions